Almost as soon as COVID-19 vaccines became available, their recipients became either “Team Pfizer” or “Team Moderna,” while competing products from AstraZeneca PLC and Johnson & Johnson quickly fell by the wayside. Novavax, Inc.’s protein-based vaccine has likewise not really caught on. But while Pfizer Inc./BioNTech SE’s Comirnaty and Moderna, Inc.’s Spikevax have quickly come to dominate the market, a panelist at the BIO CEO & Investor Conference in New York said there is still room for additional competitors despite the typical market dynamics for traditional vaccines.
Aerium Therapeutics CEO Rajeev Venkayya, who had previously served as president of the Global Vaccine Business Unit of Takeda Pharmaceutical Co. Ltd
Key Takeaways
-
During the BIO CEO conference’s panel on vaccines, Rajeev Venkayya noted it was possible for one vaccine to dominate the market for decades, pointing to Merck’s MMR vaccine as an example.
-
He cited efficacy as well as the great expense needed to challenge a vaccine’s market dominance as factors in why that is often the case
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
